Trial reportDigestive diseases and sciences2026
Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial.
Trial report in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recompensation and Further Decompensation After Index Decompensation in Patients with Autoimmune Hepatitis: A Real-World Study.Digestive diseases and sciences · 2026Article
- Autoimmune Hepatitis Treatment: Can Low-Dose Steroids Be Generalized?Digestive diseases and sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are limited data on the safety and efficacy of intravenous albumin after variceal hemorrhage (VH) in cirrhosis.
methodsPatients with cirrhosis (Child-Pugh classes B and C) with hypoalbuminemia (< 3.5 g/dL) and VH were randomized to receive either standard medical therapy (SMT) or SMT with intravenous albumin (2 g/kg, SMT + A) for 3 days after hemostasis. Hepatic venous pressure gradient (HVPG) was measured on days 1 and 3. Primary outcome was a composite of new-onset acute kidney injury (AKI), spontaneous bacterial peritonitis (SBP), hepatic encephalopathy (HE) and all-cause mortality at 6 weeks. Secondary outcomes included 5- and 42-day rebleeding rate and the need for rescue therapy.
resultsFrom December 2022 to October 2024, 136 patients were randomized, of whom 123 (SMT: 63, SMT + A: 60) patients received the allocated interventions. The median Child-Pugh and MELD score was 9 (8-10) and 14.8 (11.7-19.7), respectively. Alcohol was the leading etiology of cirrhosis. Patients receiving SMT + A had similar composite rates of HE, SBP, AKI, and all-cause mortality at 6 weeks (8 [13.3%, 95% CI 5.9 to 24.6%]) as compared to SMT alone (11 [17.5%, 95% CI 9.1 to 29.1%]; p = 0.53). There were no differences in the rates of 5-day rebleeding or mortality between the two groups. The median change in HVPG at day 3 compared to day 1 (SMT alone: 0 [- 2 to + 1.5] versus SMT + A: 0 [- 2 to + 2]; p = 0.41) was similar between both groups.
conclusionIntravenous albumin use is safe after an episode of VH in cirrhosis, but does not reduce 6-week mortality or prevent new-onset SBP/organ failures (CTRI/2022/10/046898).
Indexed as
Identifiers
41139775What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.